A Phase 2 interventional study of gemcitabine and paclitaxel in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in Japan. Open to female participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-03-16.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 49th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2006, is one of 65 in phase 2, and was the 43rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 20 Years to 74 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 63rd largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2006, is one of 41 in phase 2, and was the 31st registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
To investigate efficacy, safety and PK of gemcitabine and paclitaxel combination in patients with metastatic breast cancer after adjuvant/neo-adjuvant chemotherapy with anthracycline regimen
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: gemcitabine · Drug: paclitaxel
Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation) Phase 2: dose determined by phase 1
Also known as: LY188011, Gemzar
Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles
Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Responders are patients with complete response or partial response.
Time frame: baseline to measured progressive disease
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: time of response to progressive disease
Time to Progressive Disease
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
Time frame: baseline to measured progressive disease
Number of Participants Alive at One Year (1-Year Survival)
Time frame: baseline to date of death from any cause, evaluated at 1 year
Pharmacokinetics - Maximum Plasma Concentration (Cmax)
Maximum plasma concentration of gemcitabine plus paclitaxel on Day 1, Cycle 1, and gemcitabine monotherapy on Day 8, Cycle 1.
Time frame: cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)
Pharmacokinetics - Area Under the Concentration Curve (AUC)
Area under the concentration curve from time zero to infinity.
Time frame: cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)
Pharmacokinetics - Half Life (t½)
Apparent elimination half-life.
Time frame: cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)
| Milestone | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Started | 6 | 56 |
| Completed | 0 | 16 |
| Not completed | 6 | 40 |
| Withdrew: Progressive disease | 2 | 24 |
| Withdrew: Toxicity | 1 | 5 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Patient condition aggrevated | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Criteria for starting next cycle not met | 0 | 1 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Responders are patients with complete response or partial response.
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 3 | 25 |
| Stable Disease | 1 | 17 |
| Progressive Disease | 1 | 11 |
| Not Evaluable | 1 | 3 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| months | Dose Level 2 |
|---|---|
| Duration of Response | 4.70 (1.2 to 7.3) |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
| days | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Time to Progressive Disease | 310.5 (42 to 455) | 194.0 (29 to 265) |
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Number of Participants Alive at One Year (1-Year Survival) | 5 | 45 |
Maximum plasma concentration of gemcitabine plus paclitaxel on Day 1, Cycle 1, and gemcitabine monotherapy on Day 8, Cycle 1.
| nanograms per milliliter (ng/mL) | Gemcitabine + Paclitaxcel | Gemcitabine |
|---|---|---|
| Pharmacokinetics - Maximum Plasma Concentration (Cmax) | 25800 (12800 to 43600) | 25400 (20000 to 33100) |
Area under the concentration curve from time zero to infinity.
| nanograms*hour per milliliter (ng*hr/mL) | Gemcitabine + Paclitaxcel | Gemcitabine |
|---|---|---|
| Pharmacokinetics - Area Under the Concentration Curve (AUC) | 16300 (11700 to 25500) | 14700 (11500 to 21000) |
Apparent elimination half-life.
| hours | Gemcitabine + Paclitaxcel | Gemcitabine |
|---|---|---|
| Pharmacokinetics - Half Life (t½) | 0.282 (0.192 to 1.00) | 0.258 (0.162 to 0.969) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | — | — | — |
| Dose Level 2 | — | — | — |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Haemoglobin decreasedInvestigations | 1/6 | 0/56 |
| PneumoniaInfections and infestations | 0/6 | 1/56 |
| AnorexiaMetabolism and nutrition disorders | 0/6 | 1/56 |
| Panic disorderPsychiatric disorders | 0/6 | 1/56 |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Alanine amiontransferase increasedInvestigations | 6/6 | 44/56 |
| Haemoglobin decreasedInvestigations | 6/6 | 42/56 |
| Neutrophil count decreasedInvestigations | 4/6 | 54/56 |
| White blood cell count decreasedInvestigations | 5/6 | 52/56 |
| MalaiseGeneral disorders | 5/6 | 34/56 |
| Platelet count decreasedInvestigations | 4/6 | 39/56 |
| Aspartate aminotransferase increasedInvestigations | 4/6 | 38/56 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/6 | 34/56 |
| Lymphocyte count decreasedInvestigations | 4/6 | 28/56 |
| Blood alkaline phosphatase increasedInvestigations | 4/6 | 14/56 |
| Age Continuous(years) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Mean | 58.2 ± 4.49 | 54.4 ± 8.73 | 54.7 ± 8.46 |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Female | 6 | 56 | 62 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Japan | 6 | 56 | 62 |
| Age at Primary Diagnosis(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| <30 years old | 0 | 0 | 0 |
| 30 to <40 years old | 0 | 3 | 3 |
| 40 to <50 years old | 1 | 20 | 21 |
| 50 to <60 years old | 3 | 24 | 27 |
| 60 to <70 years old | 2 | 8 | 10 |
| ≥70 years old | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| 0 - Fully Active | 4 | 50 | 54 |
| 1 - Ambulatory, Restricted Strenuous Activity | 2 | 6 | 8 |
| Body Weight(kilograms) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Mean | 57.18 ± 15.313 | 55.76 ± 8.715 | 55.90 ± 9.375 |
| Height(centimeters) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Mean | 153.53 ± 7.987 | 154.71 ± 6.184 | 154.60 ± 6.312 |
The record gives a start of Jun 2006, a primary completion of Feb 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Paclitaxel